

REMARKS / ARGUMENTS

Claims 3-8, 12, 14-31, 38-49, 52-54, 57-60, 62-77, and 79 were indicated to be allowable in the Notice of Allowance dated July 6, 2011. Claims 80-87 are added in this Amendment. Claims 3-8, 12, 14-31, 38-49, 52-54, 57-60, 62-77, and 79-87 are currently pending.

Accompanying this submission is a Supplemental Information Disclosure Statement.

Applicants request reconsideration of the claims as amended and consideration of the Supplemental IDS.

CONCLUSION

Applicants respectfully request entry of this Amendment, and reconsideration of the application. It is believed that the application is in condition for allowance, and therefore, issuance of a Notice of Allowance is requested. Should the Examiner have any concerns regarding the foregoing, Applicants encourage the Examiner to contact the undersigned, who may be reached at (919) 483-8022.

Respectfully submitted:

/James P. Riek/

James P. Riek
Attorney of Record
Reg. No. 39,009

Date: 22 September 2011
Customer No. 23347
GlaxoSmithKline
Global Patents
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-1398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988